APTAMERS: THERAPEUTICS, TECHNOLOGIES, AND SERVICES MARKET – THE RISING REALM AMONGST STAKEHOLDERS IN PURSUIT OF ALTERNATIVE THERAPIES TO ANTIBODIES THERAPIES
Aptamers have gained a lot of momentum in the past decade. It is worth highlighting that in 2005, Macugen became the first and the only USFDA approved aptamer drug for treating age-related macular degeneration (AMD). It has been reported that more than 15 million people in the US suffer from AMD alone with 200,000 cases annually across North America. This indicates a high unmet need of patients thus, paving a way for aptamer-based solutions due to their advantages over traditional antibody-based therapies.
For additional details, please visit:- https://www.rootsanalysis.com/....reports/aptamers-the
